Quick Answer
Mineralys Therapeutics, Inc. reported Research And Development Expense of $132.01 million for the year ending 2025.
- Mineralys Therapeutics, Inc. showed a decrease of -21.7% in Research And Development Expense from 2024 to 2025.
- This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $6.78 million | Q2 2022: $5.60 million | Q3 2022: $6.06 million | Q1 2023: $12.29 million | Q2 2023: $11.88 million | Q3 2023: $22.50 million | Q1 2024: $30.75 million | Q2 2024: $39.27 million | Q3 2024: $53.99 million | Q1 2025: $37.88 million | Q2 2025: $38.28 million | Q3 2025: $31.45 million.
- Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Research And Development Expense has grown by 402.9%.
- Historical annual values: Fiscal year 2025: $132.01 million | Fiscal year 2024: $168.58 million | Fiscal year 2023: $70.36 million | Fiscal year 2022: $26.25 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: